INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX

Group 1 - A class action lawsuit has been filed against Pacira Biosciences, Inc. concerning allegations of securities fraud and unlawful business practices by the company and its officers [2][3]. - Investors who purchased Pacira securities during the Class Period have until March 14, 2025, to request appointment as Lead Plaintiff [2]. - On August 9, 2024, Pacira's stock price dropped by $10.66 per share, or 47.67%, closing at $11.70 per share following the invalidation of its '495 patent for Exparel by the U.S. District Court [3]. Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for class members [4].